<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="502">
  <stage>Registered</stage>
  <submitdate>10/09/2005</submitdate>
  <approvaldate>4/10/2005</approvaldate>
  <actrnumber>ACTRN12605000572662</actrnumber>
  <trial_identification>
    <studytitle>The effect of prophylactic preoperative probiotic therapy on perioperative endotoxin levels in cardiac surgery patients.</studytitle>
    <scientifictitle>The effect of prophylactic preoperative probiotic therapy on perioperative endotoxin levels in cardiac surgery patients.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiac surgery patients.</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a  randomised double blind placebo-controlled study  assessing blood endotoxin levels in cardiac surgery patients requiring cardiopulmonary bypass. This study compares endotoxin levels of post operative cardiac surgery patients who have received pre-operative prophylactic probiotic Lactobacillus tablets compared with patients  who have received a placebo.  Two different Lactobacillus strains will be assessed in the study, Lactobacillus acidophilus and Lactobacillus fermentum.There are 4 treatment groups in this study:Lactobacillus Fermentum, lactobacillus acidophillus, lactobacillus fermentum and acidophillus and placebo. The lactobacillus/placebo will be given to patients twice a day for between 2 to 7 days pre-operatively.Participation in the study requires six separate blood tests commencing at the start of surgery and continuing for the first 24 hours immediately post-operatively.  Each blood test requires 5 mls of blood, with a total blood volume of 30 mls required for the study.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome variable of this study is endotoxin rise in the first 24 hours post-commencement of surgery</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak IL-6 levels in the first 24 hours post-operatively.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The development of post-operative generalised inflammation and low systemic vascular resistance in the post-operative period.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass will be approached for consent to participate in the study. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current usage of a probiotic product (eg Yakult, which is freely available as a foodstuff), past history of asthma or recurrent urticaria, pregnancy, HIV infection, immunosupression and pre-existing intestinal disorder.  The Lactobacillus acidophilus preparation to be used in this study contains a very small amount of MSG (total dose 20 mg/day, equivalent to 10% of the initial dose used to test for MSG sensitivity) and as a precaution, patients with asthma or recurrent urticaria will be excluded.  As the Lactobacillus preparation contains live microrganisms, immunosupressed and pregnant patients will also be excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequentially numbered opaque envelopes.</concealment>
    <sequence>A computer generated randomisation matrix.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Unit, RMH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Intensive Care Research department Funding, Royal Melbourne Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Julian Hunt-Smith</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427710</phone>
      <fax>+61 3 93428812</fax>
      <email>julian.huntsmith@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Julian Hunt-Smith</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427710</phone>
      <fax>+61 3 93428812</fax>
      <email>julian.hunt-smith@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>